{'fraction_non_alphanumeric': 0.05211912943871707, 'fraction_numerical': 0.026918671248568157, 'mean_word_length': 5.065972222222222, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
T‐cell receptor variable region genes in cutaneous T‐cell lymphomas

The genes encoding the T‐cell receptor (TCR) variable β (TCRBV) regions were studied in skin biopsy samples from 24 patients with cutaneous T‐cell lymphomas (CTCL), i.e. mycosis fungoides (n = 7), Sézary syndrome (n = 4), lymphomatoid papulosis (n = 3) and large cell CTCL with (n = 3) or without (n = 7) CD30 expression. A panel of 24 primers specific for TCRBV families 1–24 was designed and applied to cDNA using a semiquantitative reverse transcriptase coupled polymerase chain reaction (PCR) method. Three patients showed restricted expression of a limited number (1–3) of TCRBV families. In the remaining patients, an average of 17 (range: 13–22) different families was expressed. All patients showed elevated (> 10%) expression of individual families significantly higher than that seen in normal blood lymphocytes, but no preferential usage of particular gene families was observed. Direct sequence analysis of more than 60 PCR products revealed clonal TCR transcripts in 18 patients. A single T‐cell clone, constituting 9–100% (mean: 26%) of the TCRBV mRNA, was present in 12 patients; two T‐cell clones, constituting 13–72% (mean: 21.5%) of the TCRBV mRNA, were present in five patients; and three T‐cell clones, accounting for < 0.5–13% of the TCRBV mRNA, were present in one patient. In the remaining six patients, clonal TCR transcripts could not be identified. It is concluded that most CTCL contain both clonal and non‐clonal (reactive) T cells, and that the latter cells are more numerous than anticipated. These cells may be engaged in tumour immune reactions, although prospective studies and/or serial investigations are needed to elucidate this issue fully.